eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hyperthermia |
| Comorbidity | C0278689|recurrent ovarian cancer |
| Sentences | 2 |
| PubMedID- 24657302 | Objective: evaluate the cost-effectiveness of primary prophylaxis (pp) or secondary prophylaxis (sp) with pegfilgrastim, filgrastim (6-day and 11-day), or no prophylaxis to reduce the risk of febrile neutropenia (fn) in patients with recurrent ovarian cancer receiving docetaxel or topotecan. |
| PubMedID- 20878160 | Txt 75–100 mg/m2 every 3–4 weeks is associated with a quite pronounced neutropenia, with an up to 44% rate of febrile neutropenia in patients with recurrent ovarian cancer [17]. |
Page: 1